- Home
- ALXO vs CGTX Comparison
ALXO vs CGTX Comparison
Compare ALXO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- CGTX
- Stock Information
- Founded
- ALXO 2015
- CGTX 2007
- Country
- ALXO United States
- CGTX United States
- Employees
- ALXO N/A
- CGTX N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- CGTX Health Care
- Exchange
- ALXO Nasdaq
- CGTX Nasdaq
- Market Cap
- ALXO 28.3M
- CGTX 23.1M
- IPO Year
- ALXO 2020
- CGTX 2021
- Fundamental
- Price
- ALXO $0.42
- CGTX $0.30
- Analyst Decision
- ALXO Strong Buy
- CGTX Strong Buy
- Analyst Count
- ALXO 6
- CGTX 5
- Target Price
- ALXO $3.54
- CGTX $6.13
- AVG Volume (30 Days)
- ALXO 515.3K
- CGTX 803.7K
- Earning Date
- ALXO 05-08-2025
- CGTX 05-07-2025
- Dividend Yield
- ALXO N/A
- CGTX N/A
- EPS Growth
- ALXO N/A
- CGTX N/A
- EPS
- ALXO N/A
- CGTX N/A
- Revenue
- ALXO N/A
- CGTX N/A
- Revenue This Year
- ALXO N/A
- CGTX N/A
- Revenue Next Year
- ALXO N/A
- CGTX N/A
- P/E Ratio
- ALXO N/A
- CGTX N/A
- Revenue Growth
- ALXO N/A
- CGTX N/A
- 52 Week Low
- ALXO $0.44
- CGTX $0.31
- 52 Week High
- ALXO $17.50
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- ALXO 31.14
- CGTX 31.49
- Support Level
- ALXO $0.49
- CGTX $0.40
- Resistance Level
- ALXO $0.55
- CGTX $0.47
- Average True Range (ATR)
- ALXO 0.05
- CGTX 0.04
- MACD
- ALXO 0.00
- CGTX -0.01
- Stochastic Oscillator
- ALXO 4.92
- CGTX 11.16
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.